The global Chronic Pulmonary Hypertension Drug market was valued at US$ 6312 million in 2023 and is anticipated to reach US$ 9038.2 million by 2030, witnessing a CAGR of 5.3% during the forecast period 2024-2030.

Chronic Pulmonary Hypertension Drug Market

Pulmonary hypertension happens when the pressure in the blood vessels leading from the heart to the lungs is too high. With pulmonary hypertension, the blood vessels to the lungs develop an increased amount of muscle in the wall of the blood vessels.

The chronic pulmonary hypertension drug market is driven by the increasing prevalence of pulmonary hypertension and the growing demand for effective treatment options. Chronic pulmonary hypertension is a progressive and life-threatening condition characterized by high blood pressure in the pulmonary arteries, leading to heart and lung complications. The rise in risk factors such as obesity, cardiovascular diseases, and respiratory disorders contributes to market growth. The development of novel drugs, including endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin analogs, has significantly improved patient outcomes and expanded treatment options. However, the market also faces challenges, including the complexity of managing the disease, potential side effects of medications, and the need for personalized treatment approaches. Additionally, the high cost of specialized therapies and the limited understanding of the disease's underlying mechanisms can pose obstacles for both patients and healthcare systems. To succeed, companies must focus on research and development to provide innovative and targeted drug therapies, collaborate with healthcare providers to improve disease management, and address the challenges to meet the increasing demand for effective chronic pulmonary hypertension drugs.

This report aims to provide a comprehensive presentation of the global market for Chronic Pulmonary Hypertension Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Pulmonary Hypertension Drug.

Report Scope

The Chronic Pulmonary Hypertension Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chronic Pulmonary Hypertension Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Chronic Pulmonary Hypertension Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Chronic Pulmonary Hypertension Drug Market Report

Report Metric	Details
Report Name	Chronic Pulmonary Hypertension Drug Market
Accounted market size in 2023	US$ 6312 million
Forecasted market size in 2030	US$ 9038.2 million
CAGR	5.3%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	Oral Intravenous/Subcutaneous Inhalational
Segment by Application	Hospital Pharmacy Retail Pharmacy Online Pharmacy
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Bayer, Attgeno, Cereno Scientific, Bial - Portela C S.A, Liquidia Technologies, Bellerophon Therapeutics, AbbVie Therapeutics, Insmed, Altavant Sciences, Lupin, Sun Pharmaceutical, Teva
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Pulmonary Hypertension Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Chronic Pulmonary Hypertension Drug Market growing?

Ans: The Chronic Pulmonary Hypertension Drug Market witnessing a CAGR of 5.3% during the forecast period 2024-2030.

What is the Chronic Pulmonary Hypertension Drug Market size in 2030?

Ans: The Chronic Pulmonary Hypertension Drug Market size in 2030 will be US$ 9038.2 million.

Who are the main players in the Chronic Pulmonary Hypertension Drug Market report?

Ans: The main players in the Chronic Pulmonary Hypertension Drug Market are Bayer, Attgeno, Cereno Scientific, Bial - Portela C S.A, Liquidia Technologies, Bellerophon Therapeutics, AbbVie Therapeutics, Insmed, Altavant Sciences, Lupin, Sun Pharmaceutical, Teva

What are the Application segmentation covered in the Chronic Pulmonary Hypertension Drug Market report?

Ans: The Applications covered in the Chronic Pulmonary Hypertension Drug Market report are Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

What are the Type segmentation covered in the Chronic Pulmonary Hypertension Drug Market report?

Ans: The Types covered in the Chronic Pulmonary Hypertension Drug Market report are Oral, Intravenous/Subcutaneous, Inhalational

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Chronic Pulmonary Hypertension Drug Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Oral

1.2.3 Intravenous/Subcutaneous

1.2.4 Inhalational

1.3 Market by Application

1.3.1 Global Chronic Pulmonary Hypertension Drug Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Hospital Pharmacy

1.3.3 Retail Pharmacy

1.3.4 Online Pharmacy

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Chronic Pulmonary Hypertension Drug Market Perspective (2019-2030)

2.2 Chronic Pulmonary Hypertension Drug Growth Trends by Region

2.2.1 Global Chronic Pulmonary Hypertension Drug Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Chronic Pulmonary Hypertension Drug Historic Market Size by Region (2019-2024)

2.2.3 Chronic Pulmonary Hypertension Drug Forecasted Market Size by Region (2025-2030)

2.3 Chronic Pulmonary Hypertension Drug Market Dynamics

2.3.1 Chronic Pulmonary Hypertension Drug Industry Trends

2.3.2 Chronic Pulmonary Hypertension Drug Market Drivers

2.3.3 Chronic Pulmonary Hypertension Drug Market Challenges

2.3.4 Chronic Pulmonary Hypertension Drug Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Chronic Pulmonary Hypertension Drug Players by Revenue

3.1.1 Global Top Chronic Pulmonary Hypertension Drug Players by Revenue (2019-2024)

3.1.2 Global Chronic Pulmonary Hypertension Drug Revenue Market Share by Players (2019-2024)

3.2 Global Chronic Pulmonary Hypertension Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Chronic Pulmonary Hypertension Drug Revenue

3.4 Global Chronic Pulmonary Hypertension Drug Market Concentration Ratio

3.4.1 Global Chronic Pulmonary Hypertension Drug Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Chronic Pulmonary Hypertension Drug Revenue in 2023

3.5 Chronic Pulmonary Hypertension Drug Key Players Head office and Area Served

3.6 Key Players Chronic Pulmonary Hypertension Drug Product Solution and Service

3.7 Date of Enter into Chronic Pulmonary Hypertension Drug Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Chronic Pulmonary Hypertension Drug Breakdown Data by Type

4.1 Global Chronic Pulmonary Hypertension Drug Historic Market Size by Type (2019-2024)

4.2 Global Chronic Pulmonary Hypertension Drug Forecasted Market Size by Type (2025-2030)

5 Chronic Pulmonary Hypertension Drug Breakdown Data by Application

5.1 Global Chronic Pulmonary Hypertension Drug Historic Market Size by Application (2019-2024)

5.2 Global Chronic Pulmonary Hypertension Drug Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Chronic Pulmonary Hypertension Drug Market Size (2019-2030)

6.2 North America Chronic Pulmonary Hypertension Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Chronic Pulmonary Hypertension Drug Market Size by Country (2019-2024)

6.4 North America Chronic Pulmonary Hypertension Drug Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Chronic Pulmonary Hypertension Drug Market Size (2019-2030)

7.2 Europe Chronic Pulmonary Hypertension Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Chronic Pulmonary Hypertension Drug Market Size by Country (2019-2024)

7.4 Europe Chronic Pulmonary Hypertension Drug Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Chronic Pulmonary Hypertension Drug Market Size (2019-2030)

8.2 Asia-Pacific Chronic Pulmonary Hypertension Drug Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Chronic Pulmonary Hypertension Drug Market Size by Region (2019-2024)

8.4 Asia-Pacific Chronic Pulmonary Hypertension Drug Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Chronic Pulmonary Hypertension Drug Market Size (2019-2030)

9.2 Latin America Chronic Pulmonary Hypertension Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Chronic Pulmonary Hypertension Drug Market Size by Country (2019-2024)

9.4 Latin America Chronic Pulmonary Hypertension Drug Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Chronic Pulmonary Hypertension Drug Market Size (2019-2030)

10.2 Middle East & Africa Chronic Pulmonary Hypertension Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Chronic Pulmonary Hypertension Drug Market Size by Country (2019-2024)

10.4 Middle East & Africa Chronic Pulmonary Hypertension Drug Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Bayer

11.1.1 Bayer Company Detail

11.1.2 Bayer Business Overview

11.1.3 Bayer Chronic Pulmonary Hypertension Drug Introduction

11.1.4 Bayer Revenue in Chronic Pulmonary Hypertension Drug Business (2019-2024)

11.1.5 Bayer Recent Development

11.2 Attgeno

11.2.1 Attgeno Company Detail

11.2.2 Attgeno Business Overview

11.2.3 Attgeno Chronic Pulmonary Hypertension Drug Introduction

11.2.4 Attgeno Revenue in Chronic Pulmonary Hypertension Drug Business (2019-2024)

11.2.5 Attgeno Recent Development

11.3 Cereno Scientific

11.3.1 Cereno Scientific Company Detail

11.3.2 Cereno Scientific Business Overview

11.3.3 Cereno Scientific Chronic Pulmonary Hypertension Drug Introduction

11.3.4 Cereno Scientific Revenue in Chronic Pulmonary Hypertension Drug Business (2019-2024)

11.3.5 Cereno Scientific Recent Development

11.4 Bial - Portela C S.A

11.4.1 Bial - Portela C S.A Company Detail

11.4.2 Bial - Portela C S.A Business Overview

11.4.3 Bial - Portela C S.A Chronic Pulmonary Hypertension Drug Introduction

11.4.4 Bial - Portela C S.A Revenue in Chronic Pulmonary Hypertension Drug Business (2019-2024)

11.4.5 Bial - Portela C S.A Recent Development

11.5 Liquidia Technologies

11.5.1 Liquidia Technologies Company Detail

11.5.2 Liquidia Technologies Business Overview

11.5.3 Liquidia Technologies Chronic Pulmonary Hypertension Drug Introduction

11.5.4 Liquidia Technologies Revenue in Chronic Pulmonary Hypertension Drug Business (2019-2024)

11.5.5 Liquidia Technologies Recent Development

11.6 Bellerophon Therapeutics

11.6.1 Bellerophon Therapeutics Company Detail

11.6.2 Bellerophon Therapeutics Business Overview

11.6.3 Bellerophon Therapeutics Chronic Pulmonary Hypertension Drug Introduction

11.6.4 Bellerophon Therapeutics Revenue in Chronic Pulmonary Hypertension Drug Business (2019-2024)

11.6.5 Bellerophon Therapeutics Recent Development

11.7 AbbVie Therapeutics

11.7.1 AbbVie Therapeutics Company Detail

11.7.2 AbbVie Therapeutics Business Overview

11.7.3 AbbVie Therapeutics Chronic Pulmonary Hypertension Drug Introduction

11.7.4 AbbVie Therapeutics Revenue in Chronic Pulmonary Hypertension Drug Business (2019-2024)

11.7.5 AbbVie Therapeutics Recent Development

11.8 Insmed

11.8.1 Insmed Company Detail

11.8.2 Insmed Business Overview

11.8.3 Insmed Chronic Pulmonary Hypertension Drug Introduction

11.8.4 Insmed Revenue in Chronic Pulmonary Hypertension Drug Business (2019-2024)

11.8.5 Insmed Recent Development

11.9 Altavant Sciences

11.9.1 Altavant Sciences Company Detail

11.9.2 Altavant Sciences Business Overview

11.9.3 Altavant Sciences Chronic Pulmonary Hypertension Drug Introduction

11.9.4 Altavant Sciences Revenue in Chronic Pulmonary Hypertension Drug Business (2019-2024)

11.9.5 Altavant Sciences Recent Development

11.10 Lupin

11.10.1 Lupin Company Detail

11.10.2 Lupin Business Overview

11.10.3 Lupin Chronic Pulmonary Hypertension Drug Introduction

11.10.4 Lupin Revenue in Chronic Pulmonary Hypertension Drug Business (2019-2024)

11.10.5 Lupin Recent Development

11.11 Sun Pharmaceutical

11.11.1 Sun Pharmaceutical Company Detail

11.11.2 Sun Pharmaceutical Business Overview

11.11.3 Sun Pharmaceutical Chronic Pulmonary Hypertension Drug Introduction

11.11.4 Sun Pharmaceutical Revenue in Chronic Pulmonary Hypertension Drug Business (2019-2024)

11.11.5 Sun Pharmaceutical Recent Development

11.12 Teva

11.12.1 Teva Company Detail

11.12.2 Teva Business Overview

11.12.3 Teva Chronic Pulmonary Hypertension Drug Introduction

11.12.4 Teva Revenue in Chronic Pulmonary Hypertension Drug Business (2019-2024)

11.12.5 Teva Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Liquidia Technologies

Bellerophon Therapeutics

List of Tables

Table 1. Global Chronic Pulmonary Hypertension Drug Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Oral

Table 3. Key Players of Intravenous/Subcutaneous

Table 4. Key Players of Inhalational

Table 5. Global Chronic Pulmonary Hypertension Drug Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global Chronic Pulmonary Hypertension Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 7. Global Chronic Pulmonary Hypertension Drug Market Size by Region (2019-2024) & (US$ Million)

Table 8. Global Chronic Pulmonary Hypertension Drug Market Share by Region (2019-2024)

Table 9. Global Chronic Pulmonary Hypertension Drug Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 10. Global Chronic Pulmonary Hypertension Drug Market Share by Region (2025-2030)

Table 11. Chronic Pulmonary Hypertension Drug Market Trends

Table 12. Chronic Pulmonary Hypertension Drug Market Drivers

Table 13. Chronic Pulmonary Hypertension Drug Market Challenges

Table 14. Chronic Pulmonary Hypertension Drug Market Restraints

Table 15. Global Chronic Pulmonary Hypertension Drug Revenue by Players (2019-2024) & (US$ Million)

Table 16. Global Chronic Pulmonary Hypertension Drug Market Share by Players (2019-2024)

Table 17. Global Top Chronic Pulmonary Hypertension Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Pulmonary Hypertension Drug as of 2023)

Table 18. Ranking of Global Top Chronic Pulmonary Hypertension Drug Companies by Revenue (US$ Million) in 2023

Table 19. Global 5 Largest Players Market Share by Chronic Pulmonary Hypertension Drug Revenue (CR5 and HHI) & (2019-2024)

Table 20. Key Players Headquarters and Area Served

Table 21. Key Players Chronic Pulmonary Hypertension Drug Product Solution and Service

Table 22. Date of Enter into Chronic Pulmonary Hypertension Drug Market

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Chronic Pulmonary Hypertension Drug Market Size by Type (2019-2024) & (US$ Million)

Table 25. Global Chronic Pulmonary Hypertension Drug Revenue Market Share by Type (2019-2024)

Table 26. Global Chronic Pulmonary Hypertension Drug Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 27. Global Chronic Pulmonary Hypertension Drug Revenue Market Share by Type (2025-2030)

Table 28. Global Chronic Pulmonary Hypertension Drug Market Size by Application (2019-2024) & (US$ Million)

Table 29. Global Chronic Pulmonary Hypertension Drug Revenue Market Share by Application (2019-2024)

Table 30. Global Chronic Pulmonary Hypertension Drug Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 31. Global Chronic Pulmonary Hypertension Drug Revenue Market Share by Application (2025-2030)

Table 32. North America Chronic Pulmonary Hypertension Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 33. North America Chronic Pulmonary Hypertension Drug Market Size by Country (2019-2024) & (US$ Million)

Table 34. North America Chronic Pulmonary Hypertension Drug Market Size by Country (2025-2030) & (US$ Million)

Table 35. Europe Chronic Pulmonary Hypertension Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 36. Europe Chronic Pulmonary Hypertension Drug Market Size by Country (2019-2024) & (US$ Million)

Table 37. Europe Chronic Pulmonary Hypertension Drug Market Size by Country (2025-2030) & (US$ Million)

Table 38. Asia-Pacific Chronic Pulmonary Hypertension Drug Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 39. Asia-Pacific Chronic Pulmonary Hypertension Drug Market Size by Region (2019-2024) & (US$ Million)

Table 40. Asia-Pacific Chronic Pulmonary Hypertension Drug Market Size by Region (2025-2030) & (US$ Million)

Table 41. Latin America Chronic Pulmonary Hypertension Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 42. Latin America Chronic Pulmonary Hypertension Drug Market Size by Country (2019-2024) & (US$ Million)

Table 43. Latin America Chronic Pulmonary Hypertension Drug Market Size by Country (2025-2030) & (US$ Million)

Table 44. Middle East & Africa Chronic Pulmonary Hypertension Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 45. Middle East & Africa Chronic Pulmonary Hypertension Drug Market Size by Country (2019-2024) & (US$ Million)

Table 46. Middle East & Africa Chronic Pulmonary Hypertension Drug Market Size by Country (2025-2030) & (US$ Million)

Table 47. Bayer Company Detail

Table 48. Bayer Business Overview

Table 49. Bayer Chronic Pulmonary Hypertension Drug Product

Table 50. Bayer Revenue in Chronic Pulmonary Hypertension Drug Business (2019-2024) & (US$ Million)

Table 51. Bayer Recent Development

Table 52. Attgeno Company Detail

Table 53. Attgeno Business Overview

Table 54. Attgeno Chronic Pulmonary Hypertension Drug Product

Table 55. Attgeno Revenue in Chronic Pulmonary Hypertension Drug Business (2019-2024) & (US$ Million)

Table 56. Attgeno Recent Development

Table 57. Cereno Scientific Company Detail

Table 58. Cereno Scientific Business Overview

Table 59. Cereno Scientific Chronic Pulmonary Hypertension Drug Product

Table 60. Cereno Scientific Revenue in Chronic Pulmonary Hypertension Drug Business (2019-2024) & (US$ Million)

Table 61. Cereno Scientific Recent Development

Table 62. Bial - Portela C S.A Company Detail

Table 63. Bial - Portela C S.A Business Overview

Table 64. Bial - Portela C S.A Chronic Pulmonary Hypertension Drug Product

Table 65. Bial - Portela C S.A Revenue in Chronic Pulmonary Hypertension Drug Business (2019-2024) & (US$ Million)

Table 66. Bial - Portela C S.A Recent Development

Table 67. Liquidia Technologies Company Detail

Table 68. Liquidia Technologies Business Overview

Table 69. Liquidia Technologies Chronic Pulmonary Hypertension Drug Product

Table 70. Liquidia Technologies Revenue in Chronic Pulmonary Hypertension Drug Business (2019-2024) & (US$ Million)

Table 71. Liquidia Technologies Recent Development

Table 72. Bellerophon Therapeutics Company Detail

Table 73. Bellerophon Therapeutics Business Overview

Table 74. Bellerophon Therapeutics Chronic Pulmonary Hypertension Drug Product

Table 75. Bellerophon Therapeutics Revenue in Chronic Pulmonary Hypertension Drug Business (2019-2024) & (US$ Million)

Table 76. Bellerophon Therapeutics Recent Development

Table 77. AbbVie Therapeutics Company Detail

Table 78. AbbVie Therapeutics Business Overview

Table 79. AbbVie Therapeutics Chronic Pulmonary Hypertension Drug Product

Table 80. AbbVie Therapeutics Revenue in Chronic Pulmonary Hypertension Drug Business (2019-2024) & (US$ Million)

Table 81. AbbVie Therapeutics Recent Development

Table 82. Insmed Company Detail

Table 83. Insmed Business Overview

Table 84. Insmed Chronic Pulmonary Hypertension Drug Product

Table 85. Insmed Revenue in Chronic Pulmonary Hypertension Drug Business (2019-2024) & (US$ Million)

Table 86. Insmed Recent Development

Table 87. Altavant Sciences Company Detail

Table 88. Altavant Sciences Business Overview

Table 89. Altavant Sciences Chronic Pulmonary Hypertension Drug Product

Table 90. Altavant Sciences Revenue in Chronic Pulmonary Hypertension Drug Business (2019-2024) & (US$ Million)

Table 91. Altavant Sciences Recent Development

Table 92. Lupin Company Detail

Table 93. Lupin Business Overview

Table 94. Lupin Chronic Pulmonary Hypertension Drug Product

Table 95. Lupin Revenue in Chronic Pulmonary Hypertension Drug Business (2019-2024) & (US$ Million)

Table 96. Lupin Recent Development

Table 97. Sun Pharmaceutical Company Detail

Table 98. Sun Pharmaceutical Business Overview

Table 99. Sun Pharmaceutical Chronic Pulmonary Hypertension Drug Product

Table 100. Sun Pharmaceutical Revenue in Chronic Pulmonary Hypertension Drug Business (2019-2024) & (US$ Million)

Table 101. Sun Pharmaceutical Recent Development

Table 102. Teva Company Detail

Table 103. Teva Business Overview

Table 104. Teva Chronic Pulmonary Hypertension Drug Product

Table 105. Teva Revenue in Chronic Pulmonary Hypertension Drug Business (2019-2024) & (US$ Million)

Table 106. Teva Recent Development

Table 107. Research Programs/Design for This Report

Table 108. Key Data Information from Secondary Sources

Table 109. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Chronic Pulmonary Hypertension Drug Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Chronic Pulmonary Hypertension Drug Market Share by Type: 2023 VS 2030

Figure 3. Oral Features

Figure 4. Intravenous/Subcutaneous Features

Figure 5. Inhalational Features

Figure 6. Global Chronic Pulmonary Hypertension Drug Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 7. Global Chronic Pulmonary Hypertension Drug Market Share by Application: 2023 VS 2030

Figure 8. Hospital Pharmacy Case Studies

Figure 9. Retail Pharmacy Case Studies

Figure 10. Online Pharmacy Case Studies

Figure 11. Chronic Pulmonary Hypertension Drug Report Years Considered

Figure 12. Global Chronic Pulmonary Hypertension Drug Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 13. Global Chronic Pulmonary Hypertension Drug Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 14. Global Chronic Pulmonary Hypertension Drug Market Share by Region: 2023 VS 2030

Figure 15. Global Chronic Pulmonary Hypertension Drug Market Share by Players in 2023

Figure 16. Global Top Chronic Pulmonary Hypertension Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Pulmonary Hypertension Drug as of 2023)

Figure 17. The Top 10 and 5 Players Market Share by Chronic Pulmonary Hypertension Drug Revenue in 2023

Figure 18. North America Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 19. North America Chronic Pulmonary Hypertension Drug Market Share by Country (2019-2030)

Figure 20. United States Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. Canada Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. Europe Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Europe Chronic Pulmonary Hypertension Drug Market Share by Country (2019-2030)

Figure 24. Germany Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. France Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. U.K. Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Italy Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Russia Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Nordic Countries Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Asia-Pacific Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Asia-Pacific Chronic Pulmonary Hypertension Drug Market Share by Region (2019-2030)

Figure 32. China Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Japan Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. South Korea Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Southeast Asia Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. India Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Australia Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Latin America Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Latin America Chronic Pulmonary Hypertension Drug Market Share by Country (2019-2030)

Figure 40. Mexico Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Brazil Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Middle East & Africa Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Middle East & Africa Chronic Pulmonary Hypertension Drug Market Share by Country (2019-2030)

Figure 44. Turkey Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Saudi Arabia Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Bayer Revenue Growth Rate in Chronic Pulmonary Hypertension Drug Business (2019-2024)

Figure 47. Attgeno Revenue Growth Rate in Chronic Pulmonary Hypertension Drug Business (2019-2024)

Figure 48. Cereno Scientific Revenue Growth Rate in Chronic Pulmonary Hypertension Drug Business (2019-2024)

Figure 49. Bial - Portela C S.A Revenue Growth Rate in Chronic Pulmonary Hypertension Drug Business (2019-2024)

Figure 50. Liquidia Technologies Revenue Growth Rate in Chronic Pulmonary Hypertension Drug Business (2019-2024)

Figure 51. Bellerophon Therapeutics Revenue Growth Rate in Chronic Pulmonary Hypertension Drug Business (2019-2024)

Figure 52. AbbVie Therapeutics Revenue Growth Rate in Chronic Pulmonary Hypertension Drug Business (2019-2024)

Figure 53. Insmed Revenue Growth Rate in Chronic Pulmonary Hypertension Drug Business (2019-2024)

Figure 54. Altavant Sciences Revenue Growth Rate in Chronic Pulmonary Hypertension Drug Business (2019-2024)

Figure 55. Lupin Revenue Growth Rate in Chronic Pulmonary Hypertension Drug Business (2019-2024)

Figure 56. Sun Pharmaceutical Revenue Growth Rate in Chronic Pulmonary Hypertension Drug Business (2019-2024)

Figure 57. Teva Revenue Growth Rate in Chronic Pulmonary Hypertension Drug Business (2019-2024)

Figure 58. Bottom-up and Top-down Approaches for This Report

Figure 59. Data Triangulation

Figure 60. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Temporary Myocardial Pacing Lead Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-25J15543

Wed Aug 28 00:00:00 UTC 2024

Add to Cart

Global Remote Cardiac Patient Monitoring Platform Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-12Q15835

Wed Aug 28 00:00:00 UTC 2024

Add to Cart

Global Cholesterol Vaccines Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-13X16294

Tue Aug 27 00:00:00 UTC 2024

Add to Cart

Global Mitral Valve Clip System Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-33S15377

Tue Aug 27 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions